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Abstract
Vaccine development involves time-consuming and expensive evaluation of candidate vac-
cines in animal models. As mediators of both innate and adaptive immune responses den-
dritic cells (DCs) are considered to be highly important for vaccine performance. Here we
evaluated how far the response of DCs to a vaccine in vitro is in line with the immune re-
sponse the vaccine evokes in vivo. To this end, we investigated the response of murine
bone marrow-derived DCs to whole inactivated virus (WIV) and subunit (SU) influenza vac-
cine preparations. These vaccine preparations were chosen because they differ in the
immune response they evoke in mice with WIV being superior to SU vaccine through induc-
tion of higher virus-neutralizing antibody titers and a more favorable Th1-skewed response
phenotype. Stimulation of DCs with WIV, but not SU vaccine, resulted in a cytokine re-
sponse that was comparable to that of DCs stimulated with live virus. Similarly, the gene ex-
pression profiles of DCs treated with WIV or live virus were similar and differed from that of
SU vaccine-treated DCs. More specifically, exposure of DCs to WIV resulted in differential
expression of genes in known antiviral pathways, whereas SU vaccine did not. The stronger
antiviral and more Th1-related response of DCs to WIV as compared to SU vaccine corre-
lates well with the superior immune response found in mice. These results indicate that in
vitro stimulation of DCs with novel vaccine candidates combined with the assessment of
multiple parameters, including gene signatures, may be a valuable tool for the selection of
vaccine candidates.
Introduction
Vaccination is the cornerstone in the control of many infectious diseases. The incidence of in-
fections like tetanus, measles, rubella, and polio, has declined dramatically after the
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introduction of childhood vaccination against the pathogens causing these diseases ([1,2]).
Nevertheless, there is a great need for novel and improved vaccines. No vaccines are available
yet for viruses such as HIV and Dengue virus (reviewed in [3]). In addition, there are many
vaccines that only confer a low level of protection, theMycobacterium bovis bacillus Calmette-
Guérin (BCG) vaccine against tuberculosis being a good example [4]. A better knowledge of
the mechanisms involved in immune response induction by vaccines could greatly facilitate
vaccine development.
Dendritic cells (DCs) are known to play a central role in both the innate and the adaptive
immune response against infectious organisms. Binding of microbes or microbe components
to pattern recognition receptors (PRRs) expressed by DCs, leads to the activation of various
signaling pathways within these DCs, resulting in the expression and secretion of co-stimulato-
ry molecules, chemokines and cytokines [5,6]. These DC-derived effector molecules regulate
the recruitment and activation of cells from the immune system and ultimately determine the
magnitude and phenotype of the resulting adaptive immune response. The same mechanisms
also apply to vaccine-evoked immune responses. We, therefore, studied whether distinct re-
sponses of DCs to different vaccine formulations could be identified in vitro and whether these
responses correlate with the immune responses these vaccines elicit in vivo. To this end we se-
lected two influenza vaccine formulations, whole inactivated virus (WIV) and subunit (SU)
vaccine, with well characterized immune response stimulating properties. WIV vaccines are
produced by treatment of live influenza virus with β-propiolactone or formaldehyde and retain
both the composition and the structure of the native virus. SU vaccines, on the other hand, are
produced by solubilization of inactivated virus followed by removal of the viral nucleocapsid
and purification of the viral membrane proteins hemagglutinin (HA) and neuraminidase [7].
WIV vaccine has been found to induce superior immune responses over those induced by SU
vaccine in mice as well as in unprimed human individuals. In particular, WIV evokes higher
hemaglutination inhibition (HAI) titers [8–12], generates a more favorable Th1-type response
[8], and induces cross-protective cytotoxic T cells in mice [13]. These differences can be largely
attributed to triggering of TLR7 by single-stranded viral RNA which is present in WIV but not
in SU vaccines [14].
To evaluate if in vivo immunogenicity is reflected by DC reactions in vitro we studied the
expression of activation markers, secretion of cytokines and the gene expression signature of
murine bone-marrow-derived conventional DCs (cDCs) upon stimulation with WIV or SU in-
fluenza vaccine or, for reasons of comparison, with live influenza virus. We show that WIV
and SU influenza vaccines induce different activation levels as well as distinct gene expression
profiles in cultured DCs. These in vitro vaccine signatures correlate well with immune re-
sponses elicited by these vaccines in vivo.
Material and Methods
Virus and vaccines
Egg-derived influenza A/Panama/2007/99 (H3N2) virus (A/Pan) and SU vaccine produced
from this strain were kindly provided by Solvay Biologicals (Weesp, Netherlands). WIV vac-
cine was produced by incubation of the active virus (AV) with 0.1% β-propiolactone (Acros
Organics, Geel, Belgium) in sodium citrate buffer (125 mM sodiumcitrate, 150 mM sodium
chloride, pH 8.2) for 24 hours at RT under continuous stirring. After inactivation, the virus
was dialysed against Hepes-buffered saline containing 0.1 mM EDTA (HNE buffer). This inac-
tivation procedure was performed twice. Protein content in AV, WIV and SU was determined
by Lowry assay [15]. HA content was assumed to be one third of the total viral protein for
WIV (based on the known protein composition of influenza particles and the molecular weight
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of the viral proteins) and to be equal to the total protein for SU. Equal HA amounts in the vac-
cine preparations were verified by SDS page. RT-qPCR was performed to determine the RNA
content of the vaccines using primers specific for the NP- and the M1-encoding segment. Re-
sidual RNA in SU was found to be about 0.5% of the RNA present in AV and in WIV (starting
material normalized on basis of HA content).
Animals
Twenty 16- to 17-week-old specified-pathogen-free female BALB/c mice purchased from Har-
lan Netherlands B.V. (Zeist, the Netherlands), were used for isolation of bone marrow cells for
in vitro stimulation experiments. The protocol for this animal experiment was approved by the
Animal Experimentation Ethical Committee of the University of Groningen (DEC 4381).
Culture and activation of DCs
Bone marrow (BM) was flushed from mouse femur using Iscove’s Modified Dulbecco’s Medi-
um (IMDM; Invitrogen, Bleiswijk, Netherlands). BM cells were seeded at 2x106 cells in a
100-mm petri dish (Corning, Amsterdam, Netherlands) in the presence of 200 U/ml recombi-
nant mouse (rm) GM-CSF (Peprotech, London, UK) as described in detail by Lutz et al. [16].
After 9 days of culture, the non-adherent cells were collected by gentle pipetting and 5 minutes
of centrifugation at 300 g at RT. About 90% of the non-adherent cells expressed the cDC mark-
er CD11c as revealed by staining with PECy5-labeled anti-CD11c (BD Biosciences) and flow
cytometry. 1.5x107 cDCs were seeded into a 100 mm tissue culture plastic dish (Corning) in
10 ml fresh medium containing 100 U/ml rmGM-CSF. To induce activation/maturation of the
cells, cDCs were exposed to active virus using a multiplicity of infection (MOI) of 1.5, or to dif-
ferent vaccine formulations (10 μg HA per ml). After 4, 12 and 24 hours of incubation at 37°C
non-adherent cDCs were harvested for flow-cytometric analysis and RNA extraction, and su-
pernatants were collected for cytokine quantification by multiplex immunoassay.
Flow cytometry
Characterization of cDCs after exposure to various antigens was performed by flow-cytometric
analysis. At the indicated times, cells were double-stained with monoclonal antibodies against
CD11c (PECy5) and MHC class II (FITC), CD80 (FITC), CD86 (FITC), CD40 (PE; BD Biosci-
ences), or intracellular influenza NP (FITC; Abcam). Acquisition of the samples was performed
on a flow cytometer (FACSCalibur, BD, Breda, Netherlands). A live cell gate was set on the
basis of the forward/sideward scatter and the gated cells were further evaluated for surface
marker expression. Final analysis was performed using WINlist and WinMDI. 10000 cells were
analyzed per sample.
Cytokine quantification
Cytokine levels were determined using a commercial multiplex cytokine assay (LINCO Re-
search, Inc, Missouri, USA) following the manufacturer’s protocols. Samples were analyzed on
a Luminex 100 apparatus, and calculations were performed using STarStation software (Ap-
plied Cytometry Systems, Sheffield, UK).
RNA extraction
Total RNA was isolated using TRIzol (Amersham, Roozendaal, Netherlands) to initially lyse
the cells and solubilize nucleic acids and proteins. Then chloroform was added and the watery
and organic phases were separated by centrifugation. RNA was purified from the aqueous
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phase using the RNeasy mini extraction kit (Qiagen, Hilden, Germany). The RNA content was
determined spectrophotometrically and the quality was confirmed using the RNA 6000 Nano
Assay with the Agilent 2100 Bioanalyzer (both Agilent Technologies, USA). RNA samples
were defined to be of sufficiently high quality if the electropherograms generated by the Bioa-
nalyzer demonstrated distinct 18S and 28S ribosomal RNA peaks, and when the RNA Integrity
Number (RIN) was above 8.0.
Microarray analysis
Total RNA (2.5 μg) was used as a template to synthesize double-stranded cDNA and biotin-la-
beled cRNA, using the GeneChip Expression 30-Amplification IVT Labeling kit (Affymetrix,
USA). Labelling was performed according to the manufacturer's instructions (Affymetrix,
USA). Fragmented cRNA was hybridized to mouse Affymetrix 430 2.0 microarrays, using an
Affymetrix hybridization Oven 640, washed, and subsequently scanned on a GeneChip Scan-
ner 3000 (Affymetrix).
Expression intensities were log transformed and normalized with the Variance Stabilization
normalization method using the R open statistical package. Differential gene expression was as-
sessed by Limma analysis [17]. Probe set wise comparisons between the experimental condi-
tions were performed and correction for multiple testing was achieved by requiring a false
discovery rate (FDR) of 0.05, calculated with the Benjamini-Hochberg procedure [17]. Fold
change values for probesets with limma analysis were calculated for treated versus time-
matched control. The final criterion for inclusion was a>2-fold change (FDR<0.05). The aver-
age log-ratio for treatment to control was calculated per probeset. Ratios per gene were calcu-
lated by average probesets in Spotfire. Significantly up- or downregulated gene ontologies were
identified using the annotation software package DAVID (http://david.abcc.ncifcrf.gov/). Path-
way analysis was performed using the MetaCore Analytical suite (GeneGo Inc.). Microarray
data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession
number E-MTAB-3115.
Quantitative RT- PCR
To confirm the microarray data, 17 genes were selected for RT-PCR analysis. Selected genes
were chosen on the basis of the microarray results such that the entire spectrum of high and
low fold up- or downregulation was covered. The same RNA samples were tested in RT-PCR
as were used for microarray analysis using the Applied Biosystems StepOne Instrument. The
following PCR conditions were used: 10 min 95 °C followed by 40 cycles of 15sec 94°C and
1min 60°C. SYBRgreen mastermix fromWestburg (Leusden, Netherlands) was used, and
the primers were used at 0.44μM concentration. Sequences of the primers are given in the
S1 Table.
Results
To evaluate if WIV and SU vaccine preparations could induce a measurable response in DCs
in vitro, bone-marrow-derived murine DCs were exposed to SU or WIV vaccines or to AV, all
derived from A/Pan, for 4, 12 or 24 hours. The virus and vaccine quantities were chosen such
that the vast majority of DCs exposed to active virus or WIV turned positive for influenza nu-
cleoprotein (NP) as indicated by a shift of the entire cell population to higher mean fluorescent
intensity (MFI) in FACS analysis after staining with anti-NP antibody (S1 Fig). For DCs ex-
posed to AV the MFI increased over time, indicating de novo production of NP. As expected,
in WIV-exposed DCs the MFI was low and remained constant, while DCs exposed to SU were
negative for NP throughout the experiment. Viability of cDCs cultured with the vaccine
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preparations was similar to that of controls (about 90%). However, viability of cDCs cultured
with AV was diminished at all time points (~70% (4h), ~55% (12h) and ~60% (24h)). Only live
cells were included in the analysis of surface markers. At the indicated times, cells and superna-
tants were collected for analysis of surface marker expression by flow cytometry, cytokine pro-
duction by multiplex cytokine assay and gene expression by microarray.
cDCs upregulate the expression of activation markers upon stimulation
with live influenza virus and vaccine preparations
Compared to medium-treated controls, DC cultures exposed to either virus or vaccine showed
upregulation of the activation markers CD40, CD80, and CD86 over the time course of 24
hours (Fig 1). Expression of CD40 and CD80 was hardly changed after 4 or 12 hours but was
significantly increased after 24 hours. With respect to CD86, we could distinguish a marker-
high and a marker-low population irrespective of treatment or sampling moment. Upon expo-
sure of the DCs to AV, WIV or SU, the CD86-high population increased both in MFI and in
relative proportion over time. WIV induced the most prominent upregulation of each of the
three activation markers, exposure to active virus and SU vaccine had a less pronounced and
similar effect on CD86 expression. MHC II was expressed to a high level in a proportion of
cells from 4 hours onwards. The proportion of MHC II-high cells increased with time in all
tested groups, including controls.
In summary, virus and vaccines induced activation of DCs over a time span of 24 hours, as
demonstrated by upregulation of the costimulatory molecules CD40, CD80 and CD86.
WIV but not SU vaccine induces a cytokine response in cDCs
comparable to that induced by active virus
As cytokine expression also reveals much about the activation state of the DCs, we measured
the cytokine production of virus- or vaccine-exposed DC cultures in a multiplex cytokine assay
(Fig 2). Medium-treated control cells expressed detectable amounts of the pro-inflammatory
cytokines IL-6 and TNFα but no IL-1β, IL-2, IL-10, or IL-12. DCs treated with SU vaccine,
compared to control cells, showed similar levels of IL-6 and TNFα, which increased slightly
over time. In addition, SU-treated DCs produced low levels of the T cell mitogen IL-2 at 12 and
24 hours, but none of the other cytokines studied. In contrast, in AV- and WIV-treated DC
cultures, IL-6 and TNFα levels were clearly higher than in the control samples throughout the
experiment. Already at 4 hours, these cytokines were expressed at maximum level. AV and
WIV also induced the secretion of the pro-inflammatory cytokine IL-1β at all times. IL-2 and
the Th1-steering cytokine IL-12 were expressed from 12 hours onwards, as was the case for the
immune response-dampening cytokine IL-10. The Th2-related cytokines IL-4 and IL-5 were
also measured, but expression levels of these cytokines were below the detection limit of the
assay. There were only minor differences in expression level of the various cytokines between
AV- andWIV-treated cells except for IL-1β which was consistently higher for AV-treated
DCs.
In summary, SU vaccine had only minor effects on cytokine expression by DCs, while AV
andWIV did induce the secretion of various cytokines and did so to similar extents and with
similar kinetics.
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WIV and SU vaccine preparations induce significant modification of
gene expression in DCs stimulated in vitro
To measure gene expression changes induced by the vaccine preparations or active virus we
harvested RNA from DCs at 4, 12, and 24 hours post stimulation and performed Affymetrix
mouse 430–2.0 chips assisted genome wide mRNA profiling.
Fig 1. Expression of surface activationmarkers onmurine bonemarrow-derived cDCs upon stimulation with virus or vaccine preparations. Bone
marrow cells were cultured for 9 days in the presence of GM-CSF. The resulting cDCs were then exposed to active virus (blue), WIV vaccine (green), SU
vaccine (red) or medium (black) for 4, 12 or 24 hours. Unstained cells are indicated in grey. Maturation markers CD40, CD80, CD86 and MHCII were
analyzed by flow cytometry. Histograms representative for two independent experiments are shown.
doi:10.1371/journal.pone.0125228.g001
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Global gene expression analysis by principal component analysis (PCA) on all microarrays
revealed three clusters of samples (Fig 3). The first principal component corresponds with the
stimulant used (e.g. medium, AV, SU or WIV), the second principal component corresponds
with time since stimulation. The duplicates run for each of the conditions cluster closely. The
medium control samples and SU samples cluster separately from each other and from the WIV
and AV samples which form a joint cluster.
In a first analysis we aimed to determine the gene expression signatures induced in DCs by
AV and the vaccine preparations WIV and SU. To this end, a Limma analysis was performed
to identify genes differentially regulated in virus- or vaccine-exposed DCs as compared to the
medium control. For analysis only those genes were included that were significantly
Fig 2. Cytokine production of cDCs upon stimulation with virus or vaccines. Bone marrow cells were cultured for 9 days in the presence of GM-CSF.
Cytokine production of these cDCs upon stimulation with active virus (black circles), WIV vaccine (inverted black triangles), SU vaccine (black squares) or
medium (open diamonds) for 4, 12 or 24 hours is shown. Supernatants were analyzed for the presence of the indicated cytokines by Luminex technology.
The results of two biological replicates for each condition are shown. Arrows indicate values under the detection limit.
doi:10.1371/journal.pone.0125228.g002
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(FDR<0.05) up- or downregulated compared to the corresponding medium control sample by
at least a factor of 2 in at least one of the treatment groups for at least one of the sampling mo-
ments. This resulted in the inclusion of a total of 4812 genes for further analyses. The number
of genes that were differentially expressed compared to the time-matched medium control at
each of the experimental conditions studied is depicted in Table 1. The number of differentially
regulated genes was much higher for AV- and WIV-treated DCs than for SU-treated DCs
throughout the experiment, with AV-treated DCs showing the largest differences to medium
controls. For DCs treated with AV or WIV the number of differentially expressed genes in-
creased up to 12 hours and then remained constant or decreased. Interestingly, at 4 hours
mainly upregulation occurred (56–66% of regulated genes), whereas at 12 hours the majority
of differentially regulated genes (63–70%) was downregulated. This was also the case at 24
hours although less pronounced (~55% downregulation). For SU-treated DCs relatively minor
changes in gene expression were seen which remained more or less constant over the course of
the experiment.
Fig 3. Principal component analysis of stimulation of DCs with AV, WIV, SU or medium. The numbers represent single arrays, with 2 biological
replicates per condition tested. The lines have been added to link the samples that have been treated identically but have been harvested at different time
points. The medium samples are indicated in black, SU in red, WIV in blue and AV in green. The first and second component explain 33% and 20% of the
variation in the data, and correspond to the stimulus used in the experiment and the time after the start of stimulation.
doi:10.1371/journal.pone.0125228.g003
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A hierarchical heatmap of all genes significantly up- (red) or down- (green) regulated in at
least one treatment group is shown in Fig 4. The expression profiles of AV- andWIV-treated
DCs show a high degree of similarity at 4 hours, whereas at 12- and 24 hours the expression pat-
terns start to divert from each other. Noticeably, for SU-treated cells not only the numbers of dif-
ferentially expressed genes, but also the fold changes in expression level, were overall much lower
than for AV- andWIV-treated ones. The pattern of gene expression did not resemble that in-
duced by AV at any time and showed only minor similarities with that induced byWIV.
In order to validate the microarray results the expression of 17 selected genes was measured
by qPCR. Selection was done on the basis of the microarray results such that genes covering
the entire spectrum of high and low up- or downregulation were included. For all 17 genes, the
results of microarray analysis and qPCR correlated well (S2 Table). The Pearson correlation co-
efficients of the microarray data versus the qPCR data were for the 4 hour time point 0.91, 0.93
and 0.70 for AV, WIV and SU stimulated DCs, respectively. For the 12 hour time point, this
was 0.86, 0.96 and 0.64, and for the 24 hour time point it was 0.85, 0.69 and 0.81 for the respec-
tive experimental conditions.
These results reveal that AV and WIV have a strong and similar effect on gene expression of
DCs both in terms of the number and identity of up- and downregulated genes and the fold
change in gene expression especially at the 4h time point. As expected, with time AV, which is
actively replicating, affects the expression of more genes than WIV vaccine. SU vaccine has
only moderate effects on gene expression of DCs and these effects are strongest after short
incubation.
Gene ontology and pathway analyses of regulated genes reveal
differences in regulated processes between AV, WIV and SU-treated
DCs
To determine which functional groups of genes were regulated in response to the different vac-
cine preparations, as compared to their medium control, gene ontology analyses were
Table 1. Total number of genes up- or down-regulated in DCs upon stimulation with virus or vaccine
preparations.
Number of differentially regulated genes in experimental condition
versus medium-treated DCs
group total up down
AV 4 569 373 196
WIV 4 869 486 383
SU 4 205 112 93
AV 12 2745 812 1933
WIV 12 1595 587 1008
SU 12 125 68 57
AV 24 2323 1035 1288
WIV 24 1529 676 853
SU 24 172 55 117
Gene expression was studied and significantly up- or downregulated genes were selected as described in
the legend to Figs 1 and 4.
doi:10.1371/journal.pone.0125228.t001
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performed using the functional annotation tool DAVID (http://david.abcc.ncifcrf.gov/[18–
20]). The top ten hits for each separate condition are listed in S3 Table.
At 4 hours, all top 10 gene ontologies that were upregulated upon stimulation with AV,
WIV or SU were related to immune responses (S3 Table). These ontologies included the gener-
al immune response ontology and the more specific gene ontologies response to virus, defense
response, regulation of cytokine production, innate immune responses, lymphocyte activation
and proliferation. The downregulated genes appeared to be involved in RNA processing ontol-
ogies (ribosome biogenesis, rRNA processing and metabolic processes and modification) in all
three treated groups. At 12 hours, immune response gene ontologies were still upregulated in
the AV- and WIV-treated DCs, but no longer in the SU-treated DCs. Downregulated gene on-
tologies again included RNA processing genes and were found in all three groups of treated
DCs. At 24 hours, in the AV- andWIV-treated DCs, but not in the SU-treated DCs, genes in-
volved in programmed cell death were upregulated in addition to the immune response genes.
Fig 4. Gene expression of cDCs upon stimulation with virus or vaccine preparations.Murine cDCs were cultured and stimulated as described in the
legend to Fig 1. RNA was isolated from the DCs and gene expression was measured by Affymetrix mouse 430 2.0 Genechip array. Two biological replicates
per experimental condition were used. Genes were selected that were significantly (p<0.05) regulated compared to the time-matched medium control sample
in at least one of the treatment groups at at least one of the sampling moments. This resulted in the inclusion of a total of 4812 genes into further analyses. A
heatmap of all differentially regulated genes is shown, where upregulated genes are depicted in red and downregulated genes are depicted in green.
doi:10.1371/journal.pone.0125228.g004
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Genes that were downregulated at this time mostly belonged to ontologies involved in cell
cycle regulation in all three treated groups of DCs.
The genes within the top 10 immune-related ontologies identified in AV- andWIV-treated
DCs at 4 hours were mostly differentially regulated throughout the duration of the experiment,
albeit at lower significance levels at the later time points (Fig 5). Fewer genes belonging to the
10 gene ontologies were regulated in DCs stimulated with SU than in DCs stimulated with AV
or WIV. Moreover, AV and WIV induced the regulation of genes involved in gene ontologies
“immune response” and “positive regulation of lymphocyte activation” for a longer period of
time compared to SU.
WIV vaccine induces a different gene expression signature in DCs than
SU vaccine
Previously discussed analysis was aimed at analyzing the gene expression response induced in
DCs towards AV, WIV and SU as compared to their time-matched medium controls, which
was the first aim of this study. In the following part we will address the second aim of our
study, which was to determine if the two vaccine preparations WIV and SU did indeed induce
significantly different gene signatures. In order to do so, a direct comparison of WIV- and SU-
induced gene expression was performed by Limma analysis. A total number of 515 genes were
significantly differentially regulated with a false-discovery rate<0.05 between WIV and SU-
treated DCs 4 hours after the start of the stimulation, and this number remained relatively sta-
ble at the 12 hour- and at the 24 hour time point (respectively 697 and 540) (Table 2).
Fig 5. Gene Ontologies (GO) affected in murine bonemarrow-derived cDCs upon stimulation with active virus or vaccine preparations.Data sets
obtained from the experiment described in the legend to Fig 3 were analyzed for significantly regulated GO using the annotation software package DAVID.
The top ten GO identified for AV at t = 4h are listed in the figure. Data are presented in a heatmap. Higher intensity of the red color corresponds to a higher—
log p value for the respective GO, thus to a higher probability that the respective GO was affected by the treatment.
doi:10.1371/journal.pone.0125228.g005
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Gene Ontology analysis using DAVID revealed that genes significantly higher expressed in
WIV- compared to SU-stimulated DCs were mainly genes involved in the immune response
(S4 Table). More specifically, genes belonging to the gene ontologies antigen processing, re-
sponse to virus and regulation of leukocyte responses were enriched in the higher expressed
genes in the WIV-stimulated DCs. The genes that were expressed at lower levels in WIV- as
compared to SU-stimulated DCs did not relate to any significant regulation of specific ontolo-
gies (data not shown).
The phenotype of the gene signature induced byWIV and SU in DCs in
vitro corresponds with the immune response induced by these vaccines
in vivo
We earlier reported that WIV induces type-1 IFN in plasmacytoid DCs and that immunization
of mice with WIV results in a strong immune response with a Th1 phenotype. In contrast, SU
is not capable of inducing type-1 IFN and immunization with SU results in a moderate re-
sponse with a Th2 phenotype [8]. To determine if the gene signatures in DCs exposed to WIV
and SU correspond with the distinct immune responses these two vaccines induce in vivo, we
analyzed the gene expression levels of a selection of genes known to be involved in regulating
the (Th-balance of the) immune response. The heatmap provided in Fig 6 shows that there
were clear differences in the expression of these selected genes betweenWIV- and SU-stimulat-
ed DCs.
Firstly, mRNA encoding for several transcription factors involved in the signaling cascade
for the induction of type-1 interferons, such as IRF7, IRF8 and IRF1 were found to be signifi-
cantly higher expressed in WIV- compared to SU-stimulated DCs. In addition, mRNA encod-
ing for other proteins involved in the type-1 IFN signaling pathways such as MyD88 and
STAT1 were also significantly upregulated in WIV- versus SU-stimulated DCs.
Secondly, mRNA encoding for typical effector molecules of the innate immune response,
type 1 interferons IFNα and –β, was significantly higher expressed in WIV stimulated DCs at
the 4h time point.
Thirdly, genes encoding for cytokines and co-stimulatory molecules that are known to be
involved in the humoral and cellular response against influenza virus were more strongly in-
duced in WIV- as compared to SU-stimulated DCs. mRNA coding for the Th1-type response-
mediating cytokines IL-12b, the pro-inflammatory cytokines IL-6, IL-15 and IL-1β as well as
the co-stimulatory molecules CD40, CD80 and CD86, were expressed to significantly higher
levels in WIV- compared to SU- treated DCs, and this upregulation was also maintained for
a longer period of time in these cells. The gene expression data for the cytokines- and the
Table 2. Number of genes differentially regulated in WIV- versus SU-stimulated DCs.
number of differentially regulated genes of WIV versus SU-treated
DCs
Group total up down
4h 515 285 230
12h 697 361 336
24h 540 409 131
Genes significantly differing in expression in WIV as compared to SU-stimulated DCs were determined by
Limma analysis of data from WIV- and SU-stimulated DCs, using an FDR of 0.05.
doi:10.1371/journal.pone.0125228.t002
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Fig 6. Expression signatures of selected innate immune response-related genes affected byWIV- and
SU vaccine. Heatmap showing expression in cDCs stimulated with WIV- or SU vaccine for 4, 12 and 24
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co-stimulatory molecules correlated well with respectively the measured cytokine levels (Fig 2)
and the expression of co-stimulatory molecules on the surface of these stimulated DCs (Fig 1).
Overall, fine analysis of the microarray data revealed that many immune response genes
that are known to have a major effect on the immune response phenotype and magnitude are
more strongly induced in WIV- as compared to SU-treated DCs.
Discussion
In this study, we compared the effects of influenza WIV and SU vaccines, two formulations
which largely differ in the immune response they evoke in vivo, on cultured murine DCs. The
first aim was to elucidate in how far these two vaccine preparations were capable of inducing
significant responses in terms of activation, cytokine production and gene expression of the
DCs in vitro. The second aim was to elucidate in how far the responses of DCs to the vaccines
in vitro correlate with the differential potency of these vaccines in vivo.
Addressing the first aim, we found that both vaccines induced distinct responses in cultured
DCs. However, WIV induced higher upregulation of activation markers and increased produc-
tion of cytokines as compared to SU vaccine. These results are consistent with previous studies
by us and others ([8,21]. Moreover, the gene signature induced by WIV profoundly differed
from the gene signature induced by SU. More genes were differentially regulated upon stimula-
tion with WIV as compared to SU (when compared to medium-treated DCs) and for genes
regulated by both vaccines expression was more vigorously affected by WIV than by SU. Also,
WIV activated more signaling pathways associated with immune responses than SU, and acti-
vated shared pathways to a higher extent and for a longer time period. These differences in
gene signature between WIV- and SU- stimulated DCs are most likely due to the triggering of
TLR7 by single-stranded viral RNA which is present in WIV but only in very low amounts in
SU vaccines. TLR7 triggering has been shown to result in a strong antiviral immune response,
especially the induction of type-1 interferons [22]. The role that TLR7 triggering plays in the
superior immunogenicity of WIV versus SU vaccine has been demonstrated before [14]. Theo-
retically, other RNA-detecting PRRs such as RIG-1 could also be involved in the strong re-
sponse that was triggered in the DCs by WIV. However, in earlier experiments using Flt3L-
mobilized BM-derived DCs we did not find evidence for involvement of PRRs other than
TLR7. Rather, when exposing BM-derived DCs from wt and TLR7 k.o. mice to WIV we ob-
served that surface marker upregulation and production of IFNα and IL-12p40 was strictly de-
pendent on TLR7 [14, 22, 23]. On the other hand, involvement of PRRs other than TLR7
might be dependent on the exact cell type studied since we observed that upon stimulation
with WIV pDCs purified from the spleens of TLR7 k.o. mice produced almost equal amounts
of IFNα as pDCs purified from the spleens of wt mice [14].
Having established that DCs respond to vaccines in a unique manner, the second aim of our
study was to elucidate in how far the reaction of DCs to exposure to vaccines in vitro reflects
the immune response these vaccines elicit in vivo. From studies of us and others it is known
that in naïve mice but also in naïve humans WIV induces higher HAI and virus-neutralizing
antibody titers than split virus (SV) and SU vaccines [8,14,24–26]. In line with this observation,
WIV had a much stronger effect than SU vaccine on overall gene expression and on the
hours as compared to time-matched medium control cDCs. A selection of genes is shown that are known to
be involved in transcription, the innate- and adaptive immune response. Upregulated genes are shown in red,
whereas downregulated genes are shown in green. The asterix (*) indicates that there is a significant
difference (p<0.05) in expression betweenWIV- and SU treated DCs (as measured in a direct Limma
contrast betweenWIV and SU).
doi:10.1371/journal.pone.0125228.g006
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induction of immune response-related gene ontologies and pathways in cultured DCs. The
number of differentially regulated genes and pathways, the extent of up- (and down-)regula-
tion and the duration of differential regulation were all much more pronounced in WIV-ex-
posed than in SU-exposed DCs. Furthermore, the in vivo response to WIV in mice resembled
that to infection by live influenza virus which is known to be Th1-dominated with large
amounts of IgG2a/c and IFNγ-producing T cells [8,24,25,27,28], whereas SV and SU vaccines
elicit a Th2 dominated response characterized by IgG1 and Il-4-producing Th cells [8,24,25].
One of the most pronounced differences that we found between the effects of WIV and SU
vaccines in vitro was the robust induction of mRNA encoding for type-1 interferons and many
of its upstream signaling components by WIV, but not, or to a much lower extent, by SU vac-
cine. Type-1 interferons which are produced in vivo immediately upon infection have been as-
sociated with the skewing of the immune response towards a Th1-type response by directly
interacting with B cells and also T cells [29–33]. Induction of Type-1 interferons is well in line
with the Th1 skewing of the immune responses observed in vivo upon vaccination with WIV.
Consistent with this, we found that WIV-stimulated DCs produced significantly higher
amounts of Th1-type response-mediating and pro-inflammatory cytokines like IL-12b, IL-6,
IL-1β and TNFα (both mRNA and protein), than SU-stimulated DCs. In particular, IL-12, the
key cytokine for skewing of the adaptive immune response to Th1, was found upregulated in
WIV- but not in SU-exposed DCs.
We did not detect differences in production of Th2-type response-mediating cytokines like
IL-4 and IL-5 between WIV and SU-exposed DCs and indeed production of IL-4 and IL-5 was
very low. This is not surprising since the main producers of IL-4 and IL-5 are T cells which
were not present in the assay performed. To summarize, quantitative as well as qualitative dif-
ferences in gene expression in DCs exposed to AV, WIV, or SU matched the Th1 (AV, WIV)
and Th2 (SU) phenotype of the immune response evoked by these vaccines in vivo.
Although it has to be kept in mind that in vitro DC responses might not be predictive for in
vivo immunogenicity in all cases, several studies have successfully used in vitro stimulation of
DCs to assess the immunogenic potential of vaccines and adjuvants by determining the capaci-
ty of the stimulant to induce the expression of maturation markers and/or cytokine production
after 24h of stimulation ([8,20,34,35]). Our study demonstrates that gene expression studies
can add to the information obtained from surface marker and cytokine evaluation. Gene ex-
pression studies are more sensitive than surface maker and cytokine expression studies.
Moreover, gene expression studies allow the simultaneous evaluation of a large number of re-
sponding genes and signaling pathways and have thus the potential to provide insight into the
working mechanism of a vaccine. Exploitation of this potential needs extended studies with de-
tailed analysis of gene expression patterns combined with verification of the significance of pu-
tative response pathways. This was beyond the scope of the current study. Yet, the prospect of
defining DC response profiles predictive for vaccine performance in vivo is thrilling as such
profiles could be very valuable for the selection of promising candidate vaccines as well as for
quality control of vaccine batches.
The results described in this study were obtained using murine DCs since that allowed us to
directly compare the gene expression patterns induced by exposure of DCs to AV, WIV or SU
to the immune responses these agents evoke in vivo. As a next step we will elucidate the re-
sponses of human PBMCs and/or cultured DCs to the vaccines. Interestingly, gene expression
signatures of PBMCs obtained from individuals shortly after vaccination with trivalent inacti-
vated or live attenuated influenza vaccine have recently been shown to have predictive value
for the antibody responses at 28 days post vaccination ([36,37]). Future research should estab-
lish whether a similar predictive value for in vitro stimulated cells (DCs, PBMCs or specific
combinations of cells) can be demonstrated and whether in vitro and in vivo responses of
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PBMCs/DCs to vaccines correlate. If so, a systems-biology approach of studying human cells
in vitro could prove to be valuable for the screening of vaccine candidates.
In summary, we show here that WIV- and SU vaccine preparations elicit distinct immune
signatures in cultured DCs in vitro, and that, at least for the mouse model, the immune signa-
tures evoked by WIV or SU vaccine in vitro correlate well with the magnitude and Th1/Th2
phenotype of the immune responses elicited by these vaccines in vivo. Provided that our results
in murine DCs can be extended to human cells, we propose that studying multiple facets of the
immune response of DCs in a systems-biology like fashion can provide valuable insight into
the working mechanism of vaccine candidates. Moreover, studying vaccine/adjuvant candi-
dates on DCs in vitromight enable to predict, to a certain extent, immune responses in vivo
and may therefore serve as an efficient and cost-effective tool for the selection of the most
promising vaccine candidates.
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